

**Contract No: LSSM-CT-2005-018686**

**AIDIT**

**Advancing International Co-operation and Developing  
Infrastructure for Targeted Screening of Prostate  
Cancer in Men with Genetic Predisposition**

**Instrument:** Specific Support Action

**Thematic priority 1:** Life sciences, genomics and  
biotechnology for health

**Publishable Final Activity  
Report**

**Period covered:** from December 1 2005 to May 31 2007

**Date of preparation:** 9 July 2007

**Start date of project:** December 1 2005

**Duration:** 18 months

**Project coordinator:** Dr Ros Eeles

The Institute of Cancer Research

**Revision:** Final: 9 July 2007

# Table of Contents

<b><i>Project execution</i></b>	<b>1</b>
<b>Background</b>	<b>1</b>
<b>The AIDIT Team</b>	<b>2</b>
<b>Objectives</b>	<b>3</b>
<b>Project activity</b>	<b>4</b>
The IMPACT and AIDIT website	4
The IMPACT and AIDIT conference	5
Network Development	8
<b>Dissemination and Use</b>	<b>1</b>
<b>Final plan for using and disseminating the knowledge</b>	<b>1</b>

# Project execution

## Background

In the EU, approximately 200,000 men are diagnosed annually with prostate cancer, and this figure is likely to increase due to the ageing population, causing a considerable health-care burden. Inherited genetic factors are important in this disease; for example, mutations in the breast and ovarian cancer predisposition genes *BRCA1* and *BRCA2* have also been reported to significantly increase the risk of prostate cancer, with those in *BRCA2* shown to lead to a greater increase in risk than *BRCA1*.

The European IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in *BRCA1/2* mutation carriers and controls) study aims to put in place networks and infrastructures in countries across Europe to identify a male population harbouring germline mutations in the *BRCA1* and *BRCA2* genes and to recruit these men into targeted screening programs for prostate cancer. IMPACT also aims to support future research into the targeted screening and clinical management of prostate cancer in individuals at increased risk of this disease due to a genetic predisposition.

The main goal of the AIDIT project was to stimulate co-operation between the existing IMPACT consortium and centres of excellence in the EU's associated candidate countries (ACCs) and new member states. It was intended that the project would identify and recruit appropriate research and clinical centres in the ACCs and new member states; stimulate the participation of research teams in these countries and connect expertise in all collaborating countries in this area. Networking was a crucial element of this work, which had the long-term aim of enabling centres in the ACCs to join the IMPACT study, thus establishing a larger consortium and research base.

AIDIT was also aimed at raising awareness of the need to improve clinical management of prostate cancer, educating the relevant stakeholders, improving quality of life, reducing early mortality and reducing the financial burden of health care.

## ***The AIDIT Team***

### ***The Institute of Cancer Research, London, UK (Coordinator)***

Chief Investigator – Dr Rosalind Eeles  
Project Managers – Ms Rebecca Doherty/Ms Beatrice Gehr-Swain  
IMPACT Coordinators – Ms Elizabeth Bancroft/Dr Anita Mitra  
Website Administrator – Ms Sarah Morgan  
Research Services – Dr Margaret Christie/Dr Paul Craven

### ***Pomeranian Medical University, Szczecin, Poland***

Principal Investigator: Professor Jan Lubinski  
Administrator: Dr Karolina Zieba

### ***Akdeniz University, Antalya, Turkey***

Principal Investigator: Professor Guven Luleci  
Research Fellow: Dr Esra Manguoglu

## **Objectives**

The objectives of AIDIT were to:

- Identify appropriate genetics and urology centres in the ACCs which have the expertise necessary to participate in the IMPACT study and construct a network and associated infrastructure to link appropriate centres in each ACC to the existing IMPACT consortium.
- Hold a conference to encourage networking between scientists working on the IMPACT study, and those in the ACCs, whilst ensuring that New Member States are properly represented, thereby enhancing and consolidating international cooperation and connecting expertise in all collaborating countries in this area.
- Stimulate the participation of research teams in ACCs in the IMPACT study and the subsequent facilitation of the recruitment of a target population of male *BRCA1* and 2 carriers with the long term aim of expanding the research base for the IMPACT study and therefore establishing standardised evidence-based clinical recommendations concerning the value of targeted screening for prostate cancer.
- Create a centralised project website translated into the main languages spoken in the ACCs to ensure all participating countries have easy access to information about the IMPACT study with domains for both researchers and the public enabling networking and collaboration in the IMPACT study to occur to the maximum potential.
- Raise the profile of the need for increased detection of mutations in *BRCA1* and *BRCA2* in men and for improved clinical management of prostate cancer in the ACCs and educate the relevant stakeholders through the creation of reliable, informative, and fast communication hardware and software systems.
- Disseminate the latest results from ongoing prostate cancer screening studies in the ACCs through the use of a website, international conference, media, international scientific publications and presentations.
- To appoint scientists and researchers in the ACCs onto the IMPACT Steering Committee and Specialist Committees (e.g. Data monitoring, pathology, PSA (Prostate Specific Antigen) and Hormonal Study, Biomarkers (proteomic and metabonomic), Psychological and Social Clinical Treatment, Genomic Study Committee and Bioinformatics, Ethics and Equality), following the conference, to enable scientists from all over Europe to share expertise and strengthen future collaboration in IMPACT.
- Support the implementation of Framework 6 and, in particular, the Combating Cancer topic of Thematic Priority 1 in Life Sciences, Genomics and Biotechnology for Health.


## **Project activity**

Although new contacts in the ACCs and NMSs were obtained through a range of means (including attendance at national and international conferences, publications and advertisements about the project, searching publications and websites, and contacts through colleagues), the two most important activities with regard to developing the network were the AIDIT and IMPACT website and conference.

## **The IMPACT and AIDIT website**

A major achievement of the AIDIT project has been the design, development and successful launch of a website ([www.impact-study.co.uk](http://www.impact-study.co.uk)) to serve as a tool to help raise awareness of the AIDIT project and IMPACT study in the ACCs and new member states. Design of the website and IMPACT logo (Figure 1) was carried out by Solide ([www.solide-ict.nl](http://www.solide-ict.nl)), a company subcontracted through the ICR, with text drafted by the AIDIT website administrator with input from all project partners.

*Figure 1: IMPACT study logo*



The website provides a networking forum and information resource for those both new to, and already members of, the AIDIT and IMPACT collaborations. A central information resource is critical to ensure that all centres considering joining the IMPACT collaboration have easy access to reliable and up-to-date study information and documents, including the IMPACT study protocol. The website also provides the opportunity for researchers to contact each other and strengthen future research collaborations, and to contact the IMPACT and AIDIT study offices. The website has been translated into 7 languages commonly spoken in the ACCs, and the IMPACT protocol into several languages spoken in the new member states, to make it highly accessible to collaborators in those countries.

Access to confidential information (such as study documents and discussions between collaborators) is restricted to registered users, with applications for registration from interested professionals processed by members of the AIDIT and IMPACT teams.

The website also contains unrestricted information for the general public about prostate cancer, genetics and the IMPACT study. This information was drafted with guidance from patient representatives and has been reviewed by a multicentre ethics committee in the UK. Contact details are provided on the website so that interested individuals can contact the study team. At present the information is present in English. It has also been translated into the seven common languages of the ACCs and will be made active on the website once collaborating centres have begun patient recruitment, which is not immediately possible for those centres who do not have ready access to affordable genetic testing. In the meantime, queries are handled by the AIDIT and IMPACT teams in the UK.

In the longer term, beyond AIDIT, the website will remain an important source of information for the ACCs and will be expanded to incorporate information for other countries collaborating in IMPACT as necessary. This will assist in increasing awareness about the IMPACT study and about targeted prostate cancer screening in men at high risk. The website will be updated and maintained by the IMPACT study team after the completion of the AIDIT project.


To aid rapid communication with the AIDIT and IMPACT teams, a designated IMPACT study email address has been established and linked to the website ([impact-study@icr.ac.uk](mailto:impact-study@icr.ac.uk)). This will be checked by designated members of the AIDIT and IMPACT team allowing queries from current and potential collaborators, as well as the public, to be answered quickly and accurately.

## **The IMPACT and AIDIT conference**

A major deliverable of the AIDIT Project was to host an international conference to bring together those expert collaborators in the ACCs and new member states, in all relevant fields, who hoped to take on a future role in IMPACT. The conference was planned and organised by the AIDIT Management Board, with input from the IMPACT study steering committee.

The AIDIT and IMPACT conference was held from November 28th to 30th in Szczecin, Poland, and was attended by 117 delegates from across Europe and the world. This number included current IMPACT collaborators and potential new collaborators, 21 of whom were from the ACCs and 32 from the new member states (see Figure 2). The conference was designed so that newly recruited centres of excellence in the ACCs would have the chance to form an integrated research network with current IMPACT collaborators. Key stakeholders were also invited to the conference, including healthcare providers and policy makers, regulatory authorities, potential sponsors, and patient representatives.

*Figure 2: Attendance at the AIDIT and IMPACT conference by country*



The conference was opened on the 28<sup>th</sup> of November by the Rector of Pomeranian Medical University, Professor Przemyslaw Nowacki (Figure 3). Conference proceedings included a broad range of presentations from leading experts in fields including genetics, urology, oncology, epidemiology and psychology. Panel discussions were included on each day to allow active audience participation and there was ample opportunity for informal discussion at evening social events (Figure 4).

*Figure 3, The Opening of the AIDIT and IMPACT conference by Prof Nowacki, Rector of PMU*




Figure 4: AIDIT and IMPACT Conference Welcome Mixer




The conference provided a valuable forum to discuss the practical issues of setting up the IMPACT study in participating countries and the opportunity to address any issues that have emerged or may be foreseen during these preliminary stages of the study. As this was the first time many of the delegates had met face-to-face, many new working relationships were formed. Since the conference, the AIDIT team and collaborators from the ACCs have remained in close communication.

Feedback from the conference has been overwhelmingly positive. Delegates were provided with anonymous questionnaires, with the conference graded from 1 (poor) through to 5 (excellent) as to whether it met the following goals:

- Did the meeting provide the following goals and learning outcomes:
  - a) Improved knowledge in the field of prostate cancer genetics?
  - b) Improved knowledge about participation in IMPACT study?
  - c) Development of international research networks?
- Overall rating of the quality of the education offered at this meeting
- Was the information useful and relevant to your work and practice techniques?
- Do you feel that the presented information was well balanced and supported by adequate evidence?

Averages of the responses to the questions are shown in Figure 5.

Figure 5: Participants' responses to evaluation questionnaire.



## Network Development

Collaborators from Romania, Bulgaria and Turkey have all committed to ongoing participation in IMPACT. Although in some cases access to affordable genetic testing for *BRCA1* and *BRCA2* will take time to be established, delegates in these countries have approached their health ministries to inform them of participation in IMPACT and are applying for independent funding to facilitate this. Although not included as an ACC at the time of preparing the AIDIT contract, a research team in Croatia has also expressed interest in participating in IMPACT.

Of the new member states, teams in Cyprus, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, and Slovenia have all committed to participation in IMPACT. Teams in Malta and the Czech Republic remain in contact with the collaboration but are not at this stage able to actively participate.

As well as achieving the main objective of enhancing international cooperation within IMPACT (as evidenced by the ongoing liaison with centres of excellence in Romania, Bulgaria and Turkey), the conference allowed delegates to build relationships that will benefit both clinical service delivery and other research initiatives. For example, although Malta is not able to offer thorough mutation analysis of *BRCA1* and *BRCA2*, analysis of test results of Maltese patients in the UK may identify founder mutations. This would allow affordable and rapid testing to be offered to patients within Malta. Several delegates at the conference also initiated collaborations with existing research studies such as ACTANE (an international genome-wide linkage study in familial prostate cancer) and PRACTICAL (a study that will search for new genes associated with prostate cancer susceptibility based on suggestions from earlier genome-wide association studies).

One major achievement of the conference arose from the attendance of the Chairman of the Department of Cancer Control in the Turkish Ministry of Health. Genetic testing for *BRCA1* and *BRCA2* was not previously publicly funded in Turkey. After attending the conference, hearing the presentations and discussing the importance of this testing with the Turkish delegates he made a commitment to pursue funding for this testing through the Ministry. Testing for *BRCA1* and *BRCA2* in Turkey is now available through some forms of health insurance which, while not a solution for all patients, is a significant improvement on the previous situation.

Since the conference several centres have used information from the AIDIT and IMPACT conference to lobby governments for funding, and a new Bulgarian collaborator presented information about targeted screening for men with a genetic risk of prostate cancer at a national urology meeting, furthering the efforts of AIDIT in disseminating this information.

### **Achievement of aims**

The AIDIT project, within the 18 months of its activity, fulfilled all its major aims. As occurs with every project there were some minor variations from planned activity, but these did not prevent the project from succeeding in developing a strong international network of collaborators, including representation from all the ACCs and many of the new member states. An accessible, highly informative website has been developed and a successful international conference hosted.

As expected, there was great variability in the existing genetics and oncology infrastructures across Europe, to the extent that routine testing for the *BRCA1* and *BRCA2* genes is not routinely available in several countries. As the ability to offer testing for these genes is a prerequisite for participation in IMPACT, it is therefore not possible for all centres to begin immediate patient recruitment. AIDIT had initially planned to advertise the project through local media, eg men's magazines and newspapers; however, on discussion with local centres of excellence it was decided to postpone this activity until patient recruitment is possible in each centre. Although the AIDIT and IMPACT website includes information in English aimed at the general public, it was also decided to release the translated versions on the live server only after local collaborating centres are ready. In the meantime, any queries that come from the ACCs and new member states are handled by the IMPACT team in London, with input from local centres where possible, and the IMPACT team will work with these centres to transfer this work over time.

Centres of excellence from the ACCs and new member states have therefore been integrated into the IMPACT consortium but will begin recruitment of patients at different times over the course of the study. It is likely that participation in IMPACT will allow key individuals in the ACCs to share information and resources which will be invaluable during the development of services. For example, groups setting up genetic testing for *BRCA1* and *BRCA2* may benefit from access to the testing protocols of other participating centres.

Although there was an initial plan to nominate collaborators from the ACCs to positions on IMPACT committees (including the data monitoring, pathology, PSA and Hormonal Study, Biomarkers, Psychological and Social Clinical Treatment, Genomic Study Committee and Bioinformatics, Ethics and Equality Committees), these committees are still in the process of forming. It is the intention to invite the participation of experts from the ACCs once they are firmly established; local teams within each of the ACCs have already been established.

### **Project impact**

The AIDIT project, by increasing the participation of centres of excellence in the ACCs and new member states of the EU in the IMPACT study, has helped to develop an international network that will be the first to examine the utility of targeted screening for men with a genetic predisposition to prostate cancer. The issue of how best to deliver prostate screening is controversial, with different opinions held across and within continents. It is hoped that IMPACT will guide policy with regard to the best mode of screening the group of men with the highest risk of disease.

Participation of teams from across Europe, including the ACCs and new member states, gives IMPACT the advantage of access to information about unique populations. In some regions, discrete mutations in *BRCA1* and *BRCA2* may occur more commonly than in others (known as founder mutations); if the prostate cancer that develops in these men differs in presentation or severity to prostate cancer in other parts of the world, this may lead to a better understanding of the way these genes function with regard to prostate cancer risk. This may in turn help to guide screening and treatment for both the men in these regions and those with similar mutations in other parts of the world. Whether or not these founder mutations are identified, the inclusion of men from across the world increases the likelihood that the IMPACT project will reach its target of recruiting 850 male carriers of *BRCA1* and *BRCA2* mutations and 850 controls, enabling the study to produce robust and clinically useful data that may go on to influence health care policy.

Through attendance at international meetings, dissemination activity, development of an accessible website and hosting of a successful international conference, the AIDIT project has also helped to raise the profile of the need for increased availability of genetic testing and for improved clinical management of men at high risk of prostate cancer. The project has been presented on television, in medical journals and in mainstream media, allowing information to reach a large section of the medical and lay community. The AIDIT and IMPACT conference also provided a forum for education of key stakeholders in the ACCs and new member states, with the notable success of improving access to affordable genetic testing in Turkey.

Although routine testing for *BRCA1* and *BRCA2* is not available in all countries at present, it is likely that this situation will change in the coming years. As the IMPACT study will be active over a 10-year period, centres that are establishing new genetic services will have the advantage of an existing working relationship with other centres where testing is better established. An exchange of resources and expertise will be useful in

learning from the experiences of others. This has already happened in the case of Bulgaria, where one research team has approached other members of the IMPACT consortium for advice regarding the development of testing protocols. The AIDIT Management Board is also able to direct partners to other resources, such as EuroGentest (a network for genetic test development, harmonization, validation and standardization also funded through the EC Framework 6 Programme) and the EC's FP7 Programme.

These activities all further the aim of supporting the implementation of Framework 6 and, in particular, the Combating Cancer topic of Thematic Priority 1 in Life Sciences, Genomics and Biotechnology for Health. The project has added value in the areas of genetic testing infrastructure, research sample collection and public health. The primary aims and objectives of AIDIT also address those of the specific topic reference LSH-2004-3-3 "Promotion of co-operation with Associated Candidate Countries", and hope to align the strategies and clinical management procedures of European centres with regard to the care on men with an inherited risk of prostate cancer.

## Dissemination and Use

### Final plan for using and disseminating the knowledge

Planned/actual dates	Type	Audience	Countries addressed	Size of audience	Partner
24/02/2006	Presentation at departmental away-day, Cancer Genetics Unit, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK	Cancer genetics teams, ICR and RMH	UK	30	ICR
17/03/2006	Presentation about AIDIT at IMPACT Study steering committee meeting, London, UK	International IMPACT collaborators	UK, Europe, Israel	15	ICR/PMU
06/05/06–09/05/06	Poster presentation: European Society of Human Genetics conference, Amsterdam, The Netherlands	Genetics specialists	Europe, International (59 countries)	>1700	ICR
01/05/2006	Publication of abstract: Doherty, R <i>et al</i> . AIDIT – expanding familial prostate cancer research in Eastern Europe. <i>European Journal of Human Genetics</i> 14 (Suppl 1): 227	Genetics specialists	International	unknown	All
17/05/06–20/05/06	Poster presentation at Turkish National Medical Genetics and Prenatal Diagnosis Congress, Turkey	Genetics specialists	Turkey	324	AU
17/05/06–20/05/06	Hosting of BRCA workshop at Turkish National Medical Genetics and Prenatal Diagnosis Congress, Turkey	Genetics specialists	Turkey	25	AU
22/05/2006	Presentation about IMPACT at UK Cancer Genetics Group Spring Meeting, Birmingham, UK	Genetics specialists	UK, International	150	ICR
01/06/2006	AIDIT and IMPACT conference listed on EuroGentest website ( <a href="http://www.eurogentest.org/web/db/event/87/index.xhtml">http://www.eurogentest.org/web/db/event/87/index.xhtml</a> )	Mixed	International	unknown	ICR
06/06/2006	Correspondence sent to Selena Freisens, Board Member of Central and East European Genetic Network, regarding contacts for conference	Coalition of national patient and family support groups.	Central and Eastern Europe	unknown	ICR
11/06/2006	Oral presentation, National Congress of the Turkish Association of Urology, Antalya, Turkey	Urologists	Turkey, International	1500	ICR

Planned/actual dates	Type	Audience	Countries addressed	Size of audience	Partner
15/06/06–16/06/06	Poster and oral presentation, Familial Cancer meeting, Madrid, Spain	Genetics specialists	Europe, International	150	ICR, PMU
27/06/2006	Information about AIDIT included in website for Association of FP6 Project Managers (UK) <a href="http://www2.warwick.ac.uk/services/rss/ecpmuk/">http://www2.warwick.ac.uk/services/rss/ecpmuk/</a>	FP6 project managers	UK	25	ICR
28/06/06–29/06/06	AIDIT and IMPACT posters presented at The Institute of Cancer Research Conference	Cancer Research	UK	200	ICR
01/06/2006	Morgan S et al (2006) IMPACT and AIDIT: Strengthening Research Ties in Eastern Europe. <i>Heredity Cancer in Clinical Practice</i> 4(2)	General medical	International	unknown	PMU, ICR
11/07/2006	AIDIT Project Manager listed on Ad Astra, website for the Romanian Science Community ( <a href="http://www.ad-astra.ro/whoswho/view_profile.php?user_id=1213">http://www.ad-astra.ro/whoswho/view_profile.php?user_id=1213</a> )	Romanian and international science community	Romania, International	unknown	ICR
06/08/2006–10/08/2006	Poster presentation, 11 <sup>th</sup> International Congress of Human Genetics, Brisbane, Australia	Genetics professionals	International	unknown	ICR
07/08/2006	IMPACT/AIDIT website linked to P-Mark study website ( <a href="http://www.p-mark.org/">www.p-mark.org/</a> )	Researchers/health professionals/public	International	unknown	ICR
20/08/06–24/08/06	Poster presentation, Cancer 2006: from molecular biology processes to tumor-tailored therapy, High Tatras, Slovak Republic	Health professionals, researchers	Eastern European, International	130	ICR
31/08/06–02/09/06	Poster presentation, 7 <sup>th</sup> Balkan Meeting on Human Genetics, Skopje, Macedonia	Genetic specialists	Eastern European, International	150	AU
Autumn 2006	Article about launch of the IMPACT website published in the Autumn edition of Link, the newsletter for staff of the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research	Health professionals and Cancer Research	UK, International	unknown	ICR
06/09/2006	Oral and poster presentation, Joint Breast Cancer Linkage Consortium and Cancer Genetics Group meeting, Lund, Sweden	Genetics specialists	European, International		ICR
07/09/06–09/09/06	Poster presentation, Eric K Ferrström Symposium on Cancer and Genetics, Lund, Sweden	Genetics specialists	European, International		ICR

Planned/actual dates	Type	Audience	Countries addressed	Size of audience	Partner
13/09/06–15/09/06	Poster presentation, 6th Congress of the Balkan Union of Oncology, Sofia, Bulgaria	Oncologists	Eastern European, International		ICR
19/09/2006	Oral presentation, John Radcliffe Hospital, Oxford, UK	Health professionals	UK		ICR
21/09/2006	Oral presentation, Congress of the Romanian Society of Medical Genetics, Cluj-Napoca, Romania ( <a href="http://www.trima-events.ro/htdocs/content/view/38/51/lang,en/">http://www.trima-events.ro/htdocs/content/view/38/51/lang,en/</a> )	Genetics specialists	Romania, International	130	ICR
22/09/2006	Oral presentation, British Uro-oncology Group, Nottingham, UK	Urologists, oncologists	UK		ICR
29/09/06–03/10/06	Poster presentation, European Society of Medical Oncology Congress, Istanbul, Turkey	Oncologists	European, International		ICR
08/10/06–12/10/06	Poster presentation, European Society for Therapeutic Radiology and Oncology, Leipzig, Germany	Oncologists	European, International		ICR
08/10/06 – 11/10/06	Poster presentation, National Cancer Research Institute Conference, Birmingham UK	Cancer Research	UK, International		ICR
09/10/2006	"Research Highlights" article published on the ICR website publicising the launch of the IMPACT website (including public section) <a href="http://www.icr.ac.uk/research/research_highlights/6131.shtml">http://www.icr.ac.uk/research/research_highlights/6131.shtml</a>	Health professionals, researchers, general public	UK, International	unknown	ICR
27/10/2006	IMPACT/AIDT website linked to NHS Cancer Screening Programmes website ( <a href="http://www.cancerscreening.nhs.uk/prostate/index.html">www.cancerscreening.nhs.uk/prostate/index.html</a> )	Health professionals, researchers, general public	UK, International	unknown	ICR
Oct-06	Advert published in the European Journal of Human Genetics (14; 10; October 2006), for the AIDT and IMPACT conference	Geneticists	European, International	unknown	ICR

Planned/actual dates	Type	Audience	Countries addressed	Size of audience	Partner
27/11/2006	Press release was prepared by both the Polish and UK partners and sent to: Cordiswire; Alpha Galileo; Reuters Health; Scrip; AP; PA; Medical News Today'; Reuters; Ananova; Adfero; AFX News. Articles have been published online by TVP and Medical News Today: <a href="http://www6.tvp.pl/1742/20061130427954.strona">http://www6.tvp.pl/1742/20061130427954.strona</a> <a href="http://www.medicalnewstoday.com/medicalnews.php?newsid=57618">http://www.medicalnewstoday.com/medicalnews.php?newsid=57618</a>	Health professionals, researchers, general public	European, International	unknown	ICR/PMU
27/11/2006	Press release published on Institute of Cancer Research website ( <a href="http://www.icr.ac.uk/press/press_releases_2006/6304.shtml">http://www.icr.ac.uk/press/press_releases_2006/6304.shtml</a> )	General	International	unknown	ICR
28/11/2006-30/11/06	ADIT and IMPACT conference, Szczecin, Poland ( <a href="http://impact-study.co.uk/conference/welcomingaddress">http://impact-study.co.uk/conference/welcomingaddress</a> )	Health professionals, researchers, patient representatives, policy makers, government	International, including ACCs and new member states	117	ICR/PMU/JU
28/11/2006	Television interview with Prof Jan Lubinski, Dr Ros Eeles and ADIT/IMPACT conference speakers broadcast on TVP (Polish television station)	General	Poland	unknown	PMU
28/11/2006	Online article about ADIT and IMPACT conference published by Medical News Today, <a href="http://www6.medicalnewstoday.com/medicalnews.php?newsid=57618">http://www6.medicalnewstoday.com/medicalnews.php?newsid=57618</a>	General	International	unknown	ICR
30/11/2006	Online article about ADIT and IMPACT conference published by TVP online (website for Polish broadcaster): <a href="http://www6.tvp.pl/1742/20061130427954.strona">http://www6.tvp.pl/1742/20061130427954.strona</a>	General	Poland, International	unknown	ICR/PMU
01/12/2006	ADIT/IMPACT website cited in Hodgson SV, Foulkes WD, Eng C, Maher ER (2006) <i>A Practical Guide to Human Cancer Genetics</i> (3rd Edn) Cambridge: Cambridge University Press	General medical	International	unknown	ICR

Planned/actual dates	Type	Audience	Countries addressed	Size of audience	Partner
January 2007	Conference materials from AIDIT and IMPACT conference, including abstracts, speaker biographies and presentations, released on website ( <a href="http://www.impact-study.co.uk">www.impact-study.co.uk</a> )	General (except presentations, accessible only by current and potential IMPACT collaborators)	International	Unknown	ICR
01/02/2007	Doherty R et al, on behalf of the IMPACT steering committee and collaborators (2007) Short report: The AIDIT and IMPACT conference 2006: Outcomes and future directions. <i>Heredity Cancer in Clinical Practice</i>	General medical	International	Unknown	ICR/PMU
22/02/2007 – 24/02/2007	Poster presentation, ASCO Prostate Cancer Symposium, Orlando, Florida	Urology and oncology community	International	unknown	ICR
22/05/2007 – 24/05/2007	Presentation about IMPACT at the Joint meeting of the UK Cancer Genetics Group and Dutch Cancer Society with the 10 <sup>th</sup> International Meeting on Psychosocial Aspects of Genetic Testing, Manchester, UK	Genetics specialists	UK, International	250	ICR
June 2007	Mitra AV et al (2007) A review of targeted screening for prostate cancer: introducing the IMPACT Study. <i>British Journal of Urology International</i> 99(6):1350-5.	Urology community	UK, International	unknown	ICR